Typicality: | 0.424 |
Saliency: | 0.462 |
over the past 18 months | 16 | temporal |
in designing a drug repurposing pathway | 11 | other |
on its medium-term plan | 10 | other |
group → made → significant progress | 42 |
group → make → significant progress | 16 |
group → made → substantial progress | 11 |
group → made → considerable progress | 6 |
negative | neutral | positive |
0.009 | 0.146 | 0.845 |
Raw frequency | 75 |
Normalized frequency | 0.462 |
Modifier score | 0.700 |
Perplexity | 73.157 |